BiotechTube

ZW25 (Zanidatamab) + Palbociclib + Fulvestrant

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HER2+/HR+ Breast Cancer

Conditions

HER2+/HR+ Breast Cancer

Trial Timeline

Jun 10, 2020 → Jun 30, 2025

NCT ID
NCT04224272

About ZW25 (Zanidatamab) + Palbociclib + Fulvestrant

ZW25 (Zanidatamab) + Palbociclib + Fulvestrant is a phase 2 stage product being developed by Jazz Pharmaceuticals for HER2+/HR+ Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04224272. Target conditions include HER2+/HR+ Breast Cancer.

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04224272Phase 2Completed